Kamada released FY2025 Q2 earnings on August 13 Pre-Market EST, actual revenue USD 44.75 M (forecast USD 46.41 M), actual EPS USD 0.13 (forecast USD 0.09)
Brief Summary
Kamada’s Q2 2025 earnings report revealed a revenue of $44.75 million and an EPS of $0.13, with revenue missing expectations but EPS beating the forecast.
Impact of The News
Kamada’s financial briefing for Q2 2025 provides a mixed outlook for the company:
Performance Overview:
Revenue: $44.75 million (missed expectations of $46.41 million) Reuters
Earnings Per Share (EPS): $0.13 (exceeded expectations of $0.09) Reuters
Comparison with Previous Periods:
Kamada’s revenue for the first half of 2025 was $88.8 million, showing an 11% year-over-year growth Reuters+ 2
The company’s Q2 2025 revenue grew by 5% compared to the same period last year Reuters+ 2
Adjusted EBITDA for the first half of 2025 was $22.5 million, a 35% increase from the previous year, constituting 25% of the revenue Reuters
Q2 2025 adjusted EBITDA stood at $10.9 million, marking a 20% year-over-year growth Reuters
Future Projections:
Kamada raised its full-year adjusted EBITDA guidance to a range of $40 million to $44 million Reuters
The company reaffirmed its 2025 revenue guidance of $178 million to $182 million Reuters
Kamada anticipates its Houston plasma center to contribute $8 million to $10 million annually Reuters
Market Expectations:
- Wall Street’s 12-month median target price for Kamada Ltd. is $14.00, representing a 46.6% increase from its August 12 closing price of $7.48 Reuters
Impact and Business Implications:
The mixed financial results indicate strong profitability with EPS surpassing expectations, reflecting operational efficiency and cost management
Missing revenue expectations may raise concerns about the company’s sales and market penetration strategies
The significant growth in adjusted EBITDA and the raised guidance suggest confidence in sustained profitability and operational improvements
The reaffirmed and increased revenue and EBITDA projections align with market optimism, as reflected in the substantial target price increase
Overall, Kamada’s financial health appears robust with promising profitability trends, despite some concerns regarding revenue generation. Future business developments are likely to focus on enhancing sales strategies and leveraging the expected contributions from the Houston plasma center.
